Impaired release of natural killer cytotoxic factor(s) by peripheral blood lymphocytes in patients with chronic LGL-proliferative disease.
BACKGROUND
Chronic LGL-proliferative disease (LGL-PD) is a clonal expansion of cells with large granular lymphocyte (LGL) morphology. In most cases, proliferating cells express both suppressor/cytolytic T-cell and natural killer (NK) cell surface markers, but other cell phenotypes may be observed. LGL-PD lymphocytes have been found to lack or show very low natural killer cell activity (NKa). The aim of the present paper is to investigate the underlying mechanisms responsible for impaired NKa in a homogeneous group of five selected LGL-PD patients with a CD3+, CD8+, CD57+ cell phenotype.


RESULTS
In all patients, the expanded cell population expressed very low NKa against K562 cell targets, but this increased significantly with recombinant human interleukin-2 (rhIL-2) and phytohemagglutinin (PHA) activation. Recombinant human alpha-interferon (rhIFN-alpha) had no significant effect on NKa. Cells displayed normal tumor cell binding capacity but failed to release sufficient amounts of functionally active natural killer cytotoxic factor(s) (NKCFs) upon interaction with the NK-sensitive K562 cells targets. However, they did release soluble cytolytic molecules against K562 cells upon activation with PHA.


CONCLUSIONS
Our findings provide evidence that the defective NKa in LGL-PD patients with the aforementioned phenotype is probably due, at least in part, to the inability of expanded lymphocytes to release NKCFs upon interaction with NK-sensitive cell targets. Since recognition of target cells by patient lymphocytes is not disturbed and the cells are capable of producing NKCFs upon activation with PHA, it is probable that the cause of this abnormality is located at the level of the activation signal provided by the stimulatory target cells. Studies in subcellular level are certainly needed for a more precise determination of the underlying defect.
Eliopoulos
G D
GD
Department of Hematology of the University of Crete School of Medicine, University Hospital of Heraklion, Greece.
Vaiopoulos
G
G
Kyriakou
D
D
Eliopoulos
A G
AG
Papadaki
H
H
Katrinakis
G
G
Alexandrakis
M
M
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D003603:Cytotoxins / Q000378:metabolism*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D016898:Interferon-alpha / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D008232:Lymphoproliferative Disorders / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000378:metabolism*
D015703:Antigens, CD; D003603:Cytotoxins; D016898:Interferon-alpha; D007376:Interleukin-2; D010835:Phytohemagglutinins; D011994:Recombinant Proteins